How to Deal With Cystic Fibrosis
Those with Cystic Fibrosis are often plagued by problems with their liver and digestive system, and may also suffer from infertility. If you suffer from these problems, it’s important to take steps to address them. These steps can help you live a healthy, fulfilling life.
Sweat test
Often called a “gold standard” test, the classic sweat test is used to confirm the diagnosis of cystic fibrosis. It is a non-invasive test that involves the collection of sweat in a special collector.
Sweat is produced by epithelial cells in the skin, the liver, and the lungs. If the cells in these areas are dysfunctional, they cannot produce the correct amount of sweat. Chloride, a salt, can build up in the cells and in the skin, lungs, and other organs. The high chloride levels found in sweat are a characteristic feature of CF.
A sweat test is performed for infants who are at risk of having CF. It can be performed as early as 48 hours after birth. If the test is performed in this early stage, the result is usually clear, but some infants may not produce enough sweat for reliable measurement.
A classic sweat test involves collecting sweat on filter paper and in a plastic coil. The sample is then transferred to a separate device for measurement. The results are usually returned within a few days.
Several different types of screening based on sweat testing are used. The test may also be used to detect cystic fibrosis in people with symptoms suggestive of the disease. It is especially important for infants.
Sweat tests are usually performed by a specially trained technician. Some tests are painful, but not all. If the test is being performed on a baby, the parents should stay with the child. It is best to avoid creams and lotions for at least 24 hours before the test.
Sweat testing is often used for infants who are positive on newborn screening. The test can also be performed on older children who are showing symptoms of CF.
Meconium ileus
Approximately 20% of newborns with cystic fibrosis have meconium ileus (MI). This condition usually affects newborns and is associated with a poor prognosis. However, with advancements in surgical and nonsurgical treatments, the outlook has improved.
MI is caused by the accumulation of inspissated or highly viscid meconium in the distal small bowel. This can block the ileum. In addition, pancreatic enzyme differences can cause obstruction.
If MI is not treated, it can be dangerous. Infection can occur, which can lead to shock and death. This is why it’s important to seek treatment at an early age.
Symptoms of meconium ileus include abdominal distension and failure to pass stool. In addition, infants can experience difficulty breathing. If the condition is left untreated, complications can occur, including intestinal atresia, bowel perforation, and necrosis.
Early diagnosis is important to reduce the risk of complications and improve nutrition intake. Treatment is usually given through an enema. Occasionally, N-acetylcysteine is also administered through an enema.
A diagnosis of MI can be made based on ultrasound and sonographic features. However, the diagnosis is not always made based on these sonographic features. Instead, a more accurate diagnosis is made based on the clinical findings.
When an infant is diagnosed with meconium ileus, it’s important to immediately begin treatment. There are several medications available to treat meconium ileus. Among the medications are N-acetylcysteine, diatrizoate, and Hyperosmolar agents.
Meconium ileus is a potentially lethal condition that can develop if it isn’t corrected at an early age. In addition to infection, infants with MI may also experience bowel perforation. This condition is treated by creating a stoma, or hole, in the intestine. This can prevent infection, and also prevent breast milk from passing through the digestive tract.
Digestive deficiencies
CF affects many organs and has significant effects on the gastrointestinal system. This is because the GI tract is responsible for turning food into nutrients. A properly functioning GI tract supports growth and lung function.
The GI tract consists of the small intestine, the large intestine, and the liver. The small intestine is the primary organ for nutrient absorption. Typically, people with cystic fibrosis have a hard time absorbing proteins, fat-soluble vitamins, and other micronutrients. This is because their mucus is thick. They also have problems with acid reflux and other digestive problems.
Inflammation and mucus accumulation in the intestine is another common gastrointestinal symptom in people with cystic fibrosis. The accumulation of abnormal mucus can block the digestive enzyme tubes. This can lead to infections, cirrhosis, and weight loss. If left untreated, the inflammation can lead to pancreas and liver problems.
The genetic defect that causes cystic fibrosis changes a protein that regulates salt movement from the cells. This makes people with cystic fibrosis have increased salt in their sweat. This can lead to problems with the body’s salt balance.
Cystic fibrosis patients also have decreased pancreatic function. The pancreas is a small organ that produces digestive enzymes. These enzymes help to break down food and absorb nutrients. When these enzymes are not produced, the pancreas cannot function properly. In CF, this can lead to pancreatic insufficiency, GERD, and diabetes.
CF patients also have an altered microbiome. The microbiome is the population of bacteria in the intestine. The microbiome is changed by the disease, both in location and cell density. In people with CF, the microbiome competes with the host for nutrients. These changes in the microbiome are believed to cause malnutrition in people with CF.
Liver problems
CF-related liver disease (CFLD) is a broad term used to describe liver damage in people with cystic fibrosis (CF). In fact, a number of forms of liver disease are associated with CF.
Although CFLD can be asymptomatic, it can be a serious problem. It can limit the quality of life, cause complications, and may cause death. CFLD can develop in a number of forms, including cholelithiasis, cirrhosis, and nodular regenerative hyperplasia.
Cholelithiasis is a condition that occurs in some patients with cystic fibrosis. It is usually asymptomatic, but it can progress to biliary cirrhosis.
In addition to cholelithiasis, other hepatobiliary complications of cystic fibrosis include cholecystitis and portal hypertension. In patients with portal hypertension, fluid accumulates in the abdomen and may lead to bleeding from varices. It is also accompanied by splenomegaly.
In addition, cirrhosis is the final irreversible stage of liver disease in CF patients. In advanced stages, patients may present with jaundice, ascites, coagulation process disorders, and variceal bleeding.
A liver biopsy is not routinely recommended to assess the severity of fibrosis in CF patients. However, it may be helpful in select cases.
In addition to a biopsy, imaging is also a useful tool for determining the severity of liver fibrosis. Imaging can show changes in the hepatic parenchyma, as well as portal hypertension. Imaging can also confirm the presence of cirrhosis.
In addition, serum-based biomarkers may serve as endpoints in interventional studies. These biomarkers include bilirubin and albumin levels, which may be indicative of atresia of extrahepatic bile ducts.
Treatment for CFLD is not yet proven. However, it is important to treat CFLD as early as possible to prevent complications. It should be comprehensive, with a focus on preventing liver damage.
Infertility
CF is a genetic disease that affects many of the organs in the body. This includes the reproductive system. It can affect the sperm and the vas deferens, which are responsible for carrying sperm to the penis. It also affects the pancreas, the organ which produces enzymes and mucus to regulate the digestive process.
The vas deferens is a tube that carries sperm from the testes to the penis. Without it, sperm cannot pass outside the body.
In men with cystic fibrosis, the vas deferens are missing or blocked. This causes infertility condition. It is estimated that up to 25% of CF males have idiopathic azoospermia, a condition in which the vas deferens are blocked.
Some of the treatments available for cystic fibrosis and infertility include IVF (in vitro fertilization), artificial insemination (AI), and surrogacy. The risk of birth defects in the fetus can also be increased when medications are used in ART.
Infertility in males with CF is not common. However, CF can affect the female reproductive system, leading to thrush, stress incontinence, and irregular menstruation. The cystic fibrosis transmembrane conductance regulator (CFTR) is also mutated in some males, which causes atypical cystic azoospermia.
The CFTR is also mutated in mouse sperm. Using genetic screening, genetic counselors can identify infertile males with X-linked recessive disorders, such as Kennedy’s disease.
Cystic fibrosis and infertility can be treated using IVF, surrogacy, or adoption. The risk of birth defects is also minimized when sperm are harvested and frozen before transplant surgery.
In the United States, there are approximately 16000 males with CBAVD, a disorder that occurs when the vas deferens are missing. The condition is characterized by progressive lung disease and elevated sweat electrolytes. Using assisted reproductive technologies, about 90 percent of CF males can father biological children.
Health Sources:
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
U.S. National Library of Medicine. (n.d.). https://www.ncbi.nlm.nih.gov/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Health A-Z. (2022, April 26). Verywell Health. https://www.verywellhealth.com/health-a-z-4014770
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/
